A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts

Bone Marrow Transplantation

Volumn 37, Issue 6, 2006, Pages 575-582

  Yang, H ^a   Eaves, C ^b   de Lima, M ^a   Lee, M S ^a   Champlin, R E ^a   McMannis, J D ^a   Robinson, S N ^a   Niu, T ^a   Decker, W K ^a   Xing, D ^a   Ng, J ^a   Li, S ^a   Yao, X ^a   Eaves, A C ^b   Jones, R ^a   Andersson, B S ^a   Shpall, E J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

CD34+; Chronic myelogenous leukemia (CML); Imatinib; Imatinib refractory; Mafosfamide; Purging

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; MAFOSFAMIDE; STEM CELL FACTOR; THROMBOPOIETIN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APHERESIS; ARTICLE; AUTOGRAFT; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CELL; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CELL CULTURE; CELL DIFFERENTIATION; CELL KILLING; CELL SELECTION; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; COLONY FORMING CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; EXPERIENCE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RISK REDUCTION;

ANTIGENS, CD; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; BONE MARROW PURGING; CELL SEPARATION; CELL SURVIVAL; CYCLOPHOSPHAMIDE; FLOW CYTOMETRY; HUMANS; K562 CELLS; LEUKEMIA, MYELOID, CHRONIC; NEOPLASM CIRCULATING CELLS; PIPERAZINES; PYRIMIDINES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 33644917732     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705284     Document Type: Article

References (44)

1. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
2. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928-1937.
3. Tothova E, Kafkova A, Fricova M, Benova B, Kirschnerova G, Tothova A. Imatinib mesylate in Philadelphia chromo-some-positive, chronic-phase myeloid leukemia after failure of interferon alpha. Neoplasma 2005; 52: 63-67.
4. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 2002; 99: 3530-3539.
5. Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002; 346: 683-693.
6. Marin D, Kaeda J, Szydlo R, Saunders S, Fleming A, Howard J et al. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: Patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia 2005; 19: 507-512.
7. Goldman JM. Chronic myeloid leukemia-still a few questions. Exp Hematol 2004; 32: 2-10.
8. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349:1423-1432.
9. Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005; 105: 2093-2098.
10. Horwitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: A report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996; 17: S5-S6.
11. Maziarz RT, Mauro MJ. Transplantation for chronic myelogenous leukemia: yes, no, maybe so... An Oregon perspective. Bone Marrow Transplant 2003; 32: 459-469.
12. Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068-3076.
13. Rizzoli V, Mangoni L. Pharmacological-mediated purging with mafosfamide in acute and chronic myeloid leukemias. The Italian Study Group. Prog Clin Biol Res 1990; 333: 21-36.
14. Carlo-Stella C, Mangoni L, Almici C, Caramatti C, Cottafavi L, Dotti GP et al. Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide. Bone Marrow Transplant 1994; 14: 425-432.
15. Gorin NC, Douay L, Laporte JP, Lopez M, Mary JY, Najman A et al. Autologous bone marrow transplantation using marrow incubated with Asta Z 7557 in adult acute leukemia. Blood 1986; 67: 1367-1376.
16. Shpall EJ, Jones RB, Bast Jr RC, Rosner GL, Vandermark R, Ross M et al. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: A phase I trial. J Clin Oncol 1991; 9: 85-93.
17. Topaly J, Zeller WJ, Fruehauf S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 2001; 15: 342-347.
18. Carlo-Stella C, Mangoni L, Almici C, Cottafavi L, Meloni G, Mandelli F et al. Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow. Blood 1992; 80: 2412-2418.
19. Udomsakdi C, Eaves CJ, Swolin B, Reid DS, Barnett MJ, Eaves AC. Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level. Proc Natl Acad Sci USA 1992; 89: 6192-6196.
20. Jiang X, Fujisaki T, Nicolini F, Berger M, Holyoake T, Eisterer W et al. Autonomous multi-lineage differentiation in vitro of primitive CD34+ cells from patients with chronic myeloid leukemia. Leukemia 2000; 14: 1112-1121.
21. Petzer AL, Eaves CJ, Barnett MJ, Eaves AC. Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia. Blood 1997; 90: 64-69.
22. Eaves AC, Eaves CJ, Phillips GL, Barnett MJ. Culture purging in leukemia: Past, present, and future. Leuk Lymphoma 1993; 11 (Suppl 1): 259-263.
23. Eaves AC, Barnett MJ, Ponchio L, Cashman JD, Petzer AL, Eaves CJ. Differences between normal and CML stem cells: Potential targets for clinical exploitation. Stem Cells 1998; 16 (Suppl 1): 77-83.
24. Barnett MJ, Eaves CJ, Phillips GL, Hogge DE, Klingemann HG, Lansdorp PM et al. Autografting in chronic myeloid leukemia with cultured marrow. Leukemia 1992; 6 (Suppl 4): 118-119.
25. Barnett MJ, Eaves CJ, Phillips GL, Kalousek DK, Klingemann HG, Lansdorp PM et al. Successful autografting in chronic myeloid leukaemia after maintenance of marrow in culture. Bone Marrow Transplant 1989; 4: 345-351.
26. Shpall EJ, Quinones R, Giller R, Zeng C, Baron AE, Jones RB et al. Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant 2002; 8: 368-376.
27. McNiece I, Jones R, Bearman SI, Cagnoni P, Nieto Y, Franklin W et al. Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer. Blood 2000; 96: 3001-3007.
28. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319-325.
29. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975; 45: 321-334.
30. Andersson BS, Collins VP, Kurzrock R, Larkin DW, Childs C, Ost A et al. KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts. Leukemia 1995; 9: 2100-2108.
31. Miltenyi S, Muller W, Weichel W, Radbruch A. High gradient magnetic cell separation with MACS. Cytometry 1990; 11: 231-238.
32. Cory AH, Owen TC, Barltrop JA, Cory JG. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 1991; 3: 207-212.
33. Lee WI, Kantarjian H, Glassman A, Talpaz M, Lee MS. Quantitative measurement of BCR/abl transcripts using realtime polymerase chain reaction. Ann Oncol 2002; 13: 781-788.
34. McNiece IK, Bradley TR, Kriegler AB, Hodgson GS. A growth factor produced by WEHI-3 cells for murine high proliferative potential GM-progenitor colony forming cells. Cell Biol Int Rep 1982; 6: 243-251.
35. Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr190 000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res 1998; 4: 1661-1672.
36. Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 2000; 191: 977-984.
37. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96:925-932.
38. Coutinho LH, Chang J, Brereton ML, Morgenstern GR, Scarffe JH, Harrison CJ et al. Autografting in Philadelphia (Ph)+ chronic myeloid leukaemia using cultured marrow: An update of a pilot study. Bone Marrow Transplant 1997; 19: 969-976.
39. Traycoff CM, Halstead B, Rice S, McMahel J, Srour EF, Cornetta K. Chronic myelogenous leukaemia CD34+ cells exit G0/G1 phases of cell cycle more rapidly than normal marrow CD34+ cells. Br J Haematol 1998; 102: 759-767.
40. Veena P, Cornetta K, Davidson A, Aguero B, McMahel J, Traycoff CM et al. Preferential sequestration in vitro of BCR/ ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells. Bone Marrow Transplant 1997; 19: 1213-1221.
41. Yao M, Fouillard L, Lemoine FM, Bouchet S, Firat H, Andreu G et al. Ex vivo expansion of CD34-positive peripheral blood progenitor cells from patients with non-Hodgkin's lymphoma: No evidence of concomitant expansion of contaminating bcl2/JH-positive lymphoma cells. Bone Marrow Transplant 2000; 26: 497-503.
42. Mahon FX, Pigeonnier-Lagarde V, Chahine H, Maguer-Satta V, Ripoche J, Reiffers J. Ex vivo cytokine expansion of peripheral blood Ph-negative cells in chronic myeloid leukaemia. Leuk Lymphoma 1998; 32: 151-157.
43. Eaves CJ, Eaves AC. Erythropoiesis. In: Greder DW, Takaku F (eds). Hematopoietic Stem Cell. Marcel Dekker: New York, 1985, p. 19.
44. Shpall EJ, Champlin R, Glaspy JA. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998; 4: 84-92.